Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels
- PMID: 11260417
- DOI: 10.1046/j.1523-1755.2001.0590041529.x
Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels
Abstract
Background: In a randomized, controlled trial comparing a pH neutral, bicarbonate/lactate (B/L)-buffered PD solution to conventional acidic, lactate-buffered solution (C), the overnight dialysate levels of markers of inflammation/wound healing [hyaluronic acid (HA)], mesothelial cell mass/membrane integrity [cancer antigen 125 (CA125)], and fibrosis [transforming growth factor-beta1 (TGF-beta1) and procollagen I peptides (PICP)] were assessed over a six-month treatment period.
Methods: One hundred six patients were randomized (2:1) to either the B/L group or C group. Overnight effluents were collected at entry into the study (time = 0 all patients on control solution) and then at three and six months after randomization. Aliquots were filtered, stored frozen, and assayed for HA, CA125, TGF-beta1, and PICP. Differences between groups were assessed by repeated-measures analysis of variance for unbalanced data using the SAS procedure MIXED.
Results: In patients treated with B/L, there was a significant (P = 0.03) increase in CA125 after six months compared with time = 0 (19.76 +/- 11.8 vs. 24.4 +/- 13.8 U/mL; mean +/- SD; N = 51). In the same group of patients, HA levels were significantly decreased at both three and six months in the B/L-treated group (time = 0, 336.0 +/- 195.2; time = 3 months, 250.6 +/- 167.6; and time = 6 months, 290.5 +/- 224.6 ng/mL; mean +/- SD; P = 0.006, N = 47 and P = 0.003, N = 48, respectively). No significant changes in CA125 or HA levels were observed in the control group. There were no significant changes observed in the levels of PICP or TGF-beta1 in the B/L or C group over the six-month treatment period.
Conclusions: These results suggest that continuous therapy with the B/L solutions modulates the levels of putative markers of peritoneal membrane integrity and inflammation. In the long term, this may positively impact the peritoneal membrane, increasing its life as a dialyzing organ.
Similar articles
-
The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.Kidney Int. 2004 Jul;66(1):408-18. doi: 10.1111/j.1523-1755.2004.00747.x. Kidney Int. 2004. PMID: 15200450 Clinical Trial.
-
The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.Ren Fail. 2008;30(2):161-7. doi: 10.1080/08860220701808384. Ren Fail. 2008. PMID: 18300115
-
Effects of Icodextrin and Glucose Bicarbonate/Lactate-Buffered Peritoneal Dialysis Fluids on Effluent Cell Population and Biocompatibility Markers IL-6 and CA125 in Incident Peritoneal Dialysis Patients.Ther Apher Dial. 2016 Apr;20(2):149-57. doi: 10.1111/1744-9987.12391. Epub 2016 Mar 1. Ther Apher Dial. 2016. PMID: 26929256
-
Peritoneal fluid markers of mesothelial cells and function.Adv Ren Replace Ther. 1998 Jul;5(3):205-11. doi: 10.1016/s1073-4449(98)70033-0. Adv Ren Replace Ther. 1998. PMID: 9686631 Review.
-
Cancer antigen 125 as a biomarker in peritoneal dialysis: mesothelial cell health or death?Perit Dial Int. 2013 Jul-Aug;33(4):349-52. doi: 10.3747/pdi.2012.00320. Perit Dial Int. 2013. PMID: 23843586 Free PMC article. Review.
Cited by
-
Characterization of peritoneal dialysis effluent-derived cells: diagnosis of peritoneal integrity.J Artif Organs. 2013 Mar;16(1):74-82. doi: 10.1007/s10047-012-0673-1. Epub 2012 Dec 30. J Artif Organs. 2013. PMID: 23274627
-
Pathophysiology of the peritoneal membrane during peritoneal dialysis: the role of hyaluronan.J Biomed Biotechnol. 2011;2011:180594. doi: 10.1155/2011/180594. Epub 2011 Dec 12. J Biomed Biotechnol. 2011. PMID: 22203782 Free PMC article. Review.
-
Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions.Int Urol Nephrol. 2007;39(1):299-312. doi: 10.1007/s11255-006-9064-y. Epub 2006 Sep 27. Int Urol Nephrol. 2007. PMID: 17004033 Review.
-
Effects of long-term treatment with low-GDP, pH-neutral solutions on peritoneal membranes in peritoneal dialysis patients.Clin Exp Nephrol. 2019 May;23(5):689-699. doi: 10.1007/s10157-018-1679-7. Epub 2018 Dec 13. Clin Exp Nephrol. 2019. PMID: 30547267
-
A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation.Perit Dial Int. 2012 May-Jun;32(3):305-15. doi: 10.3747/pdi.2010.00115. Epub 2011 Nov 1. Perit Dial Int. 2012. PMID: 22045100 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous